June 24, 2020 / 7:58 PM / 13 days ago

BRIEF-Acceleron Presents Topline Results Of The Pulsar Phase 2 Trial Of Sotatercept In Patients With Pulmonary Arterial Hypertension

June 24 (Reuters) - Acceleron Pharma Inc:

* ACCELERON PRESENTS TOPLINE RESULTS OF THE PULSAR PHASE 2 TRIAL OF SOTATERCEPT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

* ACCELERON PHARMA INC - PULSAR TRIAL ACHIEVED ITS PRIMARY ENDPOINT

* ACCELERON PHARMA - PULSAR TRIAL ACHIEVED ITS PRIMARY ENDPOINT

* ACCELERON PHARMA INC - SOTATERCEPT WAS GENERALLY WELL TOLERATED

* ACCELERON PHARMA - PULSAR TRIAL ACHIEVED STATISTICALLY SIGNIFICANT ALL-DOSE MEAN IMPROVEMENT FROM BASELINE OF 54 METERS IN KEY SECONDARY ENDPOINT

* ACCELERON PHARMA - ADVERSE EVENTS CONSISTENT WITH PREVIOUSLY PUBLISHED DATA ON SOTATERCEPT IN CLINICAL TRIALS IN OTHER PATIENT POPULATIONS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below